• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Verana Health launches Qdata Uveitic Macular Edema module

News
Article

The UME module adds to the list of ophthalmic diseases available in the dataset.

(Image Credit: AdobeStock/NicoElNino)

(Image Credit: AdobeStock/NicoElNino)

Verana Health announced the launch of its Qdata Uveitic Macular Edema (UME) module, a dataset containing curated variables such as visual acuity (VA), central subfield thickness (CST) and intraocular pressure (IOP).

Qdata are research-ready, fit-for-purpose data modules designed to confidently drive business insights and inform research outcomes, according to the company. It integrates exclusive structured and unstructured electronic health record (EHR) data from the American Academy of Ophthalmology Intelligent Research in Sight (IRIS) Registry. The IRIS Registry includes over 783 million patient encounters, 80 million unique patients, and 15 thousand contributing clinicians.1

Verana states that the dataset can “support clinical development, health economics and outcomes research, and medical affairs teams by accelerating therapy development, monitoring real-world treatment patterns and outcomes, and informing site selection and patient identification.”

In a press release shared with Ophthalmology Times, Verana Health described the new Qdata module as “a major advancement in the management and treatment of UME.” The Qdata UME module follows recent announcements from Verana about the development of other Qdata modules in dry eye disease (DED) and thyroid eye disease (TED).

Sujay Jadhav, CEO of Verana Health, discussed the development of the UME module in the press release.

"While there are effective steroid treatments for UME, it often requires regular injections to prevent the disease from progressing to the point of vision loss. This highlights a real need to understand the best treatment plan based on patient characteristics and demographics,” said Jadhav. "Our Qdata UME module addresses a significant gap in UME research and treatment by going beyond standard diagnostic codes and identifying key variables that can be extracted from clinician notes within EHRs to help evaluate the efficacy of treatments.”

Qdata is not limited to ophthalmology and also has modules in the fields of urology and neurology.

References:
  1. Verana Health Ophthalmology Qdata.Accessed May 30, 2024. https://veranahealth.com/solutions/ophthalmology-qdata/
Related Videos
© 2024 MJH Life Sciences

All rights reserved.